Drug Trial Radar · NCT04977024
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Actual
Start
Sep 27, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- GeoVax, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from entering healthy cells. The immune system also grows new disease fighting T cells that can recognize and destroy infected cells. Giving GEO-CM04S1 after cellular therapy may work better in reducing the chances of contracting coronavirus disease 2019 (COVID-19) or developing a severe form of COVID-19 disease in patients with blood cancer compared to SOC mRNA SARS-CoV-2 vaccine.
Conditions
- COVID-19 Infection
- Hematopoietic and Lymphoid System Neoplasm
- Leukemia
- Lymphoma
- Plasma Cell Myeloma
Interventions
COVID-19 VaccineBiological
Receive SOC mRNA SARS-CoV-2 vaccine IM
Diagnostic Laboratory Biomarker AnalysisOther
Correlative studies
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Biological
Given IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biological responseTime frame: At 28 days post the second vaccine injection
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California
Johns Hopkins University
Baltimore, Maryland
U Mass Chan Medical School
Worcester, Massachusetts
SUNY-Stony Brook
Stony Brook, New York
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina
Fred Hutchinson Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.